Valuation: Emergent BioSolutions Inc.

Market Cap 349M 313M 288M 261M 487M 33.15B 496M 3.43B 1.38B 17.44B 1.31B 1.28B 55B P/E 2026 *
-1.47x
P/E 2027 * 95.4x
Enterprise Value 719M 644M 593M 537M 1B 68.3B 1.02B 7.07B 2.84B 35.93B 2.7B 2.64B 113B EV / Sales 2026 *
1.09x
EV / Sales 2027 * 0.94x
Free-Float
43.4%
Yield 2026 *
-
Yield 2027 * -
1 day-5.68%
1 week+9.31%
1 month+3.18%
3 months-5.68%
6 months-17.25%
Current year-44.90%
1 week 6.14
Extreme 6.14
7.3
1 month 6.01
Extreme 6.01
7.65
Current year 4.36
Extreme 4.36
14.06
1 year 4.36
Extreme 4.36
14.06
3 years 1.42
Extreme 1.42
15.1
5 years 1.42
Extreme 1.42
52.76
10 years 1.42
Extreme 1.42
137.61
Manager TitleAgeSince
Chief Executive Officer 70 21/02/2024
Director of Finance/CFO 62 26/03/2018
Compliance Officer 55 01/03/2020
Director TitleAgeSince
Chairman 82 01/04/2022
Director/Board Member 70 01/01/2005
Director/Board Member 77 01/10/2016
Date Insider Type Main position Quantity % Market Cap. Importance
10/7/26 A Sell

Director

-17,800 0.0347%
10/1/26 A Sell

Executive/Senior Manager

-3,000 0.0059%
8/5/26 A Other

Executive/Senior Manager

455,311 0.8824%
Change 5-day change 1-year change 3-year change Capi.($)
-5.68%+9.31%-45.43%+225.84% 349M
+3.19%+11.31%+64.28%+155.91% 1,263B
-0.73%+3.56%+44.65%+84.17% 658B
+1.41%+3.24%+35.25%+108.88% 521B
+0.42%+3.20%+55.81%+72.50% 391B
+2.18%+2.93%+73.90%+45.59% 369B
+1.12%+4.52%+34.76%+58.24% 307B
+6.96%+8.86%+11.95%+36.20% 290B
+1.15%+6.09%+56.15%+82.25% 252B
+3.06%+9.38%+42.48%+117.32% 212B
Average +1.31%+6.24%+37.38%+98.69% 426.23B
Weighted average by Cap. +2.01%+6.60%+50.50%+100.45%

Financials

2026 *2027 *
Net sales 657M 589M 541M 491M 917M 62.39B 934M 6.46B 2.59B 32.82B 2.47B 2.41B 104B 703M 630M 579M 525M 981M 66.78B 1B 6.91B 2.77B 35.13B 2.64B 2.58B 111B
Net income -239M -214M -197M -178M -334M -22.71B -340M -2.35B -943M -11.94B -897M -878M -37.67B 3.83M 3.43M 3.15M 2.86M 5.34M 363M 5.44M 37.59M 15.09M 191M 14.36M 14.05M 603M
Net Debt 370M 332M 305M 276M 516M 35.15B 526M 3.64B 1.46B 18.49B 1.39B 1.36B 58.31B 309M 277M 254M 231M 431M 29.33B 439M 3.03B 1.22B 15.43B 1.16B 1.13B 48.65B
Projected Income Statement - Annual - Emergent BioSolutions Inc.
Logo Emergent BioSolutions Inc.
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
Employees
900
Date Price Change Volume
30/10/26 $6.810 -5.68% 754,436
29/10/26 $7.220 +1.83% 682,382
28/10/26 $7.090 +6.30% 800,815
27/10/26 $6.670 +5.21% 1,504,651
26/10/26 $6.340 +1.77% 485,438
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Emergent BioSolutions Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
6.810USD
Average target price
11.00USD
Spread / Average Target
+61.53%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Emergent BioSolutions Inc.